Serum Institute of India stopped Covishield production due to reduced demand post high vaccination rates. They disclosed rare side effects like Thrombosis with thrombocytopenia syndrome since 2021, emphasizing transparency commitment. AstraZeneca acknowledged this rare side effect.

​Serum Institute of India stopped Covishield production due to reduced demand post high vaccination rates. They disclosed rare side effects like Thrombosis with thrombocytopenia syndrome since 2021, emphasizing transparency commitment. AstraZeneca acknowledged this rare side effect. 

​